India markets closed

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.33-0.32 (-1.35%)
At close: 4:00PM EDT
23.33 0.00 (0.00%)
After hours: 04:03PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 51.17B
Enterprise value 3771.07M
Trailing P/E N/A
Forward P/E 1-4.71
PEG Ratio (5 yr expected) 1-0.65
Price/sales (ttm)N/A
Price/book (mrq)2.58
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7-5.26

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-11.42%
S&P500 52-week change 335.10%
52-week high 338.49
52-week low 317.51
50-day moving average 326.29
200-day moving average 329.10

Share statistics

Avg vol (3-month) 3242.82k
Avg vol (10-day) 3115.83k
Shares outstanding 550.2M
Implied shares outstanding 6N/A
Float 29.42M
% held by insiders 14.98%
% held by institutions 189.61%
Shares short (14-Jul-2021) 42.26M
Short ratio (14-Jul-2021) 410.15
Short % of float (14-Jul-2021) 410.84%
Short % of shares outstanding (14-Jul-2021) 44.51%
Shares short (prior month 14-Jun-2021) 42.28M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30-Dec-2020
Most-recent quarter (mrq)30-Mar-2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.26%
Return on equity (ttm)-41.48%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -146.49M
Net income avi to common (ttm)-143.71M
Diluted EPS (ttm)-3.47
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)444.93M
Total cash per share (mrq)8.86
Total debt (mrq)5.05M
Total debt/equity (mrq)1.12
Current ratio (mrq)30.43
Book value per share (mrq)9.04

Cash flow statement

Operating cash flow (ttm)-138.23M
Levered free cash flow (ttm)-90.02M